First Time Loading...

Geron Corp
NASDAQ:GERN

Watchlist Manager
Geron Corp Logo
Geron Corp
NASDAQ:GERN
Watchlist
Price: 3.87 USD 3.75%
Updated: May 8, 2024
Section:
 

Wall Street
Price Targets

GERN Price Targets Summary
Geron Corp

Wall Street analysts forecast GERN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GERN is 5.9 USD with a low forecast of 4.55 USD and a high forecast of 10.5 USD.

GERN Lowest Forecast
Wall Street Target
4.55 USD
17% Upside
GERN Average Forecast
Wall Street Target
5.9 USD
52% Upside
GERN Highest Forecast
Wall Street Target
10.5 USD
171% Upside
Lowest
Price Target
4.55 USD
17% Upside
Average
Price Target
5.9 USD
52% Upside
Highest
Price Target
10.5 USD
171% Upside

GERN Last Price Targets
Geron Corp

The latest public price target was made on Apr 30, 2024 by Joel Beatty from Robert W. Baird , who expects GERN stock to rise by 16% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Joel Beatty
Robert W. Baird
4.5 USD
Upside 16%
1 week ago
Apr 30, 2024
Baird Downgrades Geron Corporation (GERN) to Neutral 'on Valuation Concerns'
StreetInsider
Gil Blum
Needham
5 USD
Upside 29%
1 month ago
Mar 15, 2024
Geron Corporation (GERN) PT Raised to $5 at Needham, 'anticipate imetelstat will receive the go-ahead on or prior to its June 16 PDUFA date'
StreetInsider
Corinne Jenkins
Goldman Sachs
5 USD
Upside 29%
1 month ago
Mar 15, 2024
Geron Corporation (GERN) PT Raised to $5 at Goldman Sachs
StreetInsider
Joel Beatty
Robert W. Baird
Price Target 4.5 USD
Upside/Downside 16%
View Source
Gil Blum
Needham
Price Target 5 USD
Upside/Downside 29%
View Source
Corinne Jenkins
Goldman Sachs
Price Target 5 USD
Upside/Downside 29%
View Source
Geron Corp Competitors:
Price Targets
CYTH
Cyclo Therapeutics Inc
116% Upside
H
042520
Hans Biomed Corp
178% Upside
VRTX
Vertex Pharmaceuticals Inc
16% Upside
ARWR
Arrowhead Pharmaceuticals Inc
126% Upside
CYTH
Cyclo Therapeutics Inc
116% Upside
H
042520
Hans Biomed Corp
178% Upside
VRTX
Vertex Pharmaceuticals Inc
16% Upside
ARWR
Arrowhead Pharmaceuticals Inc
126% Upside
SRZN
Surrozen Inc
238% Upside
VCYT
Veracyte Inc
50% Upside
C
049960
Cell Biotech Co Ltd
364% Upside
VCEL
Vericel Corp
11% Upside

Revenue
Forecast

Revenue Estimate
Geron Corp

For the last 8 years the compound annual growth rate for Geron Corp's revenue is -47%. The projected CAGR for the next 3 years is 1 220%.

-47%
Past Growth
1 220%
Estimated Growth
Estimates Accuracy
1%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Geron Corp

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Geron Corp

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-71%
Average Miss
What are analyst estimates?

See Also

Summary
GERN intrinsic value, competitors valuation, and company profile.
DCF Valuation
GERN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GERN stock valuation using valuation multiples.
Wall Street Estimates
GERN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GERN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is GERN's stock price target?
Price Target
5.9 USD

According to Wall Street analysts, the average 1-year price target for GERN is 5.9 USD with a low forecast of 4.55 USD and a high forecast of 10.5 USD.

What is Geron Corp's Revenue forecast?
Projected CAGR
1 220%

For the last 8 years the compound annual growth rate for Geron Corp's revenue is -47%. The projected CAGR for the next 3 years is 1 220%.

ALPHA SPREAD
Join more than 135,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.